摘要
目的观察地榆生白片在非小细胞肺癌化疗中预防化疗所致白细胞减少的疗效。方法42例非小细胞肺癌患者随机分为观察组和对照组,观察组(21例)采用地榆生白片加PC(Paclitaxel+Carboplatin)方案治疗,对照组(21例)采用PC方案化疗,观察二者骨髓抑制程度及集落刺激因子用量。结果观察组Ⅲ度及Ⅳ度骨髓抑制发生率47.6%、显著低于对照组90.5%(P<0.05);应用集落刺激因子均能使化疗后白细胞下降的患者白细胞上升至正常范围(>4×109/L)。但观察组和对照组白细胞升至正常范围的时间平均为(3.47±0.38)天和(5.29±1.10)天,观察组、对照组人均集落刺激因子(150μg)用量分别为(3.62±1.09)支和(6.90±0.62)支,差异有显著性(P<0.05)。结论地榆生白片可减轻非小细胞肺癌化疗的骨髓抑制作用,加速外周血白细胞的恢复,减轻化疗风险,有利于化疗的顺利进行。且价格低廉,效果好,故可配合集落刺激因子广泛应用。
Objective To observe the effects of Diyushengbai tablet(DY) on leucocyte decreasing in chemotherrpy of non-small cell lung cancer (NSCLC). Methods 42 patients of NSCLC were randomized into two groups: observational group (21 patients, PC+DY), control group (19 patients, PC only). To investigate the medullary inhibition lever and the quantity of colony stimulating factor being used. Results The rate of Ⅲ and Ⅳ medullary inhibition was 29.0% in observational group was significant lower than in control group of 62.0%(P< 0.05). The colony stimulating factor could turn the down leucocyt up to snuff (>4×109/L). It took average 3.5and 5 days in observational group and control group respectively. The quantity of colony stimulating factor (150μg) being used in observational group and control group were 0.58± 1.99 and 1.93± 3.62 respectively and it had a significant difference with P< 0.05. Conclusion DY is better in the chemotherapy of NSCLC by decerasing the medullary inhibition, improving the down leucocyt and reducing the risk of chemotherapy. DY has a better effect and low price and can be used together with colony stimulating factor in clinic.
出处
《肿瘤防治研究》
CAS
CSCD
北大核心
2005年第7期436-437,共2页
Cancer Research on Prevention and Treatment
关键词
非小细胞肺癌
地榆生白片
骨髓抑制
Non-small cell lung cancer
Diyushengbai tablet
Myelosuppression
